Webcast From Improving Outcomes in Gynecologic Cancers - prIME Oncology
Webcast
Webcast

Webcast From Improving Outcomes in Gynecologic Cancers

PARP Inhibition and Immunotherapeutic Approaches

Not a member of My prIME? Join now for instant access.

Stay engaged in recent updates and key findings in PARP inhibition and immunotherapy in gynecologic malignancies with this webcast from our virtual grand rounds series.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

1.0 AMA PRA Category 1 Credit(s)

Release Date

Release Date

Jul 12, 2019

Expiration Date

Jul 12, 2020

Improving Outcomes in Gynecologic Cancers: PARP Inhibition and Immunotherapeutic Approaches
Joyce Liu, MD, PhD

  • Joyce Liu, MD, PhDDana Farber Cancer Institute
    Boston, Massachusetts

This activity is intended for gynecologic oncologists, medical oncologists, oncology nurses, and other members of the cancer care team involved in the management of gynecologic malignancies.

After successful completion of this educational activity, participants should be able to:

  • Incorporate PARP inhibitors into treatment regimens for patients with ovarian cancer
  • Devise effective strategies for treating patients with ovarian and cervical cancer with checkpoint inhibitors and PARP inhibitors, both alone or in combination
  • Describe safety and efficacy data of PARP inhibition and immunotherapy in endometrial cancer

NURSING LEARNING OBJECTIVES

  • Identify FDA-approved therapies for patients with ovarian cancer
  • Develop communication tools for relaying the efficacy and safety of approved treatments for gynecologic cancers to patients

This educational activity is supported by grants from AstraZeneca; Clovis Oncology; Merck and Co, Inc.; and TESARO, Inc.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Provider

This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 1.0 hour(s)

To contact Postgraduate Institute for Medicine please visit www.pimed.com.

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Liu has disclosed that she has received consulting fees from AstraZeneca, Tesaro, Clovis, and Merck.

The Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships

The employees of prIME Oncology have disclosed:

  • Angela Zimmermann, PhD (scientific content manager) – worked on non–CME certified projects in the last 12 months supported by AstraZeneca, Merck, Novartis, and Pfizer
  • Susan McKinney (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.